Recent Company News

• 03:04 AM ET Aug 25, 2025
  

  Biogen, Eisai to launch LEQEMBI in Austria today ($139.31, 0.00)

• 07:47 PM ET Aug 17, 2025
  

  Eisai launches in-house developed anti-insomnia drug DAYVIGO (lemborexant) in China (¥4638.0000, 0)

• 01:10 AM ET Aug 12, 2025
  

  Newron Pharmaceuticals begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS) (CHF 7.74, 0.00)

• 01:03 AM ET Aug 11, 2025
  

  Newron Pharmaceuticals notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction (CHF 7.47, 0.00)

• 11:34 PM ET Aug 04, 2025
  

  Eisai reports Q1 net income attributable ¥14.47B vs FactSet ¥13.60B [4 est, ¥4.30-19.40B] (¥4399.0000, +95)

• 11:11 AM ET Jul 30, 2025
  

  Two-year real-world study of LEQEMBI in the U.S. presented at Alzheimer's Association International Conference (AAIC) 2025 ($128.30, +0.40)

• 08:12 AM ET Jul 30, 2025
  

  Eisai continue announces latest findings demonstrating continued benefit from four years of LEQEMBI (lecanemab-irmb) therapy in early Alzheimer's patients in new clinical data presented at AAIC (¥4200.0000, 0)

• 02:08 AM ET Jul 22, 2025
  

  BioArctic partner Eisai will present the latest findings on lecanemab (Leqembi), including four-year efficacy and safety data and data on the subcutaneous formulation for maintenance dosing at AAIC 2025 (SEK 196.00, 0.00)

• 01:03 AM ET Jul 09, 2025
  

  Price of Eisai's LEQEMBI to be cut by up to 15% in Japan following MHLW report (10:00 JST/22:00 ET/03:00 CET) (¥4033.0000, +33)

• 02:37 AM ET Jul 08, 2025
  

  Medivir receives Notice of Allowance for fostrox plus lenvatinib combination patent by Japan Patent Office (SEK 1.52, 0.00)